Andrea Wang-Gillam, Co-CEO at Jacobio Pharma, shared Jacobio Pharma’s post on LinkedIn, adding:
“Excited to see our Pan-KRAS inhibitor advance into the frontline PDAC setting!”
Quoting Jacobio Pharma:
“Jacobio Pharma is pleased to announce that the first patient has been dosed in our Phase I/III clinical study evaluating JAB-23E73, our oral pan-KRAS inhibitor, in combination with nab-paclitaxel and gemcitabine as a first-line treatment for KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). This marks an important milestone in the clinical development of JAB-23E73.
A sincere thank you to the patients, investigators, and clinical teams who made this milestone possible.”
Learn more here.
More posts featuring Jacobio Pharma and Andrea Wang-Gillam on OncoDaily.